Novo Nordisk wins design award for NovoFine® Autocover®
(9 Apr 2008)
Novo Nordisk has been awarded a 2008 Medical Design Excellence Award for NovoFine® Autocover® – a needle for insulin injection designed especially to reduce the risk of needle stick injuries and help people with diabetes who suffer from needle anxiety.
Each year, around 1,000 healthcare professionals in the US are injured by serious infections from needle sticks and sharps. Needle-stick injuries are preventable. American Nurses Association estimates that more than 80% of needle-stick injuries could be prevented with the use of safer needle devices. Needle-stick injuries can expose healthcare professionals to serious infections – as hepatitis B, hepatitis C, and HIV – and each needle-stick injury can be costly for society, even when no infection occurs.
NovoFine® Autocover® is designed to conceal the needle during injection and may therefore help diabetes patients overcome needle anxiety. As many as 10% of people with diabetes suffer from a fear of needles, to the point where they actually avoid injections.
NovoFine® Autocover® has currently been launched in the US, UK, Spain, Italy, the Netherlands, Denmark, France and Ireland. It is used with the Novo Nordisk FlexPen® and other Novo Nordisk insulin injection devices.
Since its inception in 1998, the Medical Design Excellence Awards programme has become the premier competition for the medical technology industry, recognising both the design achievements and healthcare contributions of medical product manufacturers. The award programme is sponsored by Medical Device & Diagnostic Industry (MD&DI)) magazine. Entries excel in the areas of product innovation, design and engineering achievement, end-user benefit, and cost-effectiveness in manufacturing and healthcare delivery
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.
For further information please contact: